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Type 1 diabetes (T1D) is a complex disease characterized by the loss
of insulin-secreting β-cells. Although the disease has a strong ge-
netic component, and several loci are known to increase T1D
susceptibility risk, only few causal genes have currently been iden-
tiﬁed. To identify disease-causing genes in T1D,we performed an in
silico “phenome–interactome analysis” on a genome-wide linkage
scan dataset. This method prioritizes candidates according to their
physical interactions at the protein level with other proteins in-
volved in diabetes. A total of 11 genes were predicted to be likely
disease genes in T1D, including the INS gene. An unexpected top-
scoring candidate gene was huntingtin-interacting protein (HIP)-
14/ZDHHC17. Immunohistochemical analysis of pancreatic sections
demonstrated that HIP14 is almost exclusively expressed in insulin-
positive cells in islets of Langerhans. RNAi knockdown experiments
established that HIP14 is an antiapoptotic protein required for β-cell
survival and glucose-stimulated insulin secretion. Proinﬂammatory
cytokines (IL-1β and IFN-γ) that mediate β-cell dysfunction in T1D
down-regulated HIP14 expression in insulin-secreting INS-1 cells
and in isolated rat and human islets. Overexpression of HIP14
was associated with a decrease in IL-1β–induced NF-κB activity
and protection against IL-1β–mediated apoptosis. Our study
demonstrates that the current network biology approach is a valid
method to identify genes of importance for T1D andmay therefore
embody the basis for more rational and targeted therapeutic
approaches.
autoimmunity | huntington’s disease | protein network | bioinformatics |
programmed cell death
Type 1 diabetes (T1D) is a polygenetic multifactorial auto-immune disease in which the insulin-producing pancreatic
β-cells in the islets of Langerhans are destroyed during an in-
ﬂammatory process known as insulitis (1). Genes in the HLA
region are by far the most important T1D susceptibility genes (2,
3). The largest and most recent genome-wide association and
linkage studies revealed more than 40 genomic regions with
signiﬁcant association to T1D (4, 5). These insights, however, do
not lead to identiﬁcation of the causative variants and the spe-
ciﬁc disease genes in these regions. The main challenge is that
most of the identiﬁed risk loci contain several genes, and pri-
oritization of these is difﬁcult.
An increasing number of integrative bioinformatics tools have
been applied to disease susceptibility data with the aim of pri-
oritizing the positional candidate genes. This has mainly been
performed by integrating genetic data and other data, such as
gene expression or text mining (6–9). These approaches have
recently been further developed on the assumption that cellular
functions and disease phenotypes are regulated by the co-
ordinated actions of proteins working together in protein com-
plexes and pathways (10–13). Therefore, causal genetic variants
in a complex disease such as T1D are likely to translate into
changed functionality of a protein network or pathway causing
a change in the biological and phenotypic outcome. These kinds
of strategies have also been applied on T1D and T2D (14–16) but
without biological and functional evaluation of candidate genes.
We developed a unique in silico “phenome–interactome net-
work analysis” for predicting proteins involved in disease (17).
Starting from high-conﬁdence human protein–protein interaction
data, networks for proteins encoded by genes in associated loci
are generated. This is followed by scoring and ranking of the
proteins according to phenotypic association to disease of the
individual proteins in the network, and all candidates are awarded
a posterior probability between 0 and 1 on the basis of these data
(17). Thus, a candidate is considered likely to be involved in T1D
if it interacts physically at the protein level (using only high-con-
ﬁdence interaction data) with proteins already known to be in-
volved in diabetes risk or etiology. Candidates with such a proﬁle
will be awarded a high probability by the phenome–interacome
prediction method. In the present study, we have applied this
method on a T1D genome-wide linkage study (GWLS) dataset (3)
to identify T1D candidate proteins. In addition to 10 other pro-
teins, we identiﬁed Huntingtin-interacting protein (HIP)-14 as
a candidate protein. Functional studies demonstrated that HIP14
is expressed in β-cells, is required for β-cell survival, and is a target
of proinﬂammatory cytokines known to contribute to β-cell de-
struction in T1D.
Results
Phenome–Interactome Network Analysis Predicts 11 T1D Candidate
Proteins. To identify unique disease genes/proteins in T1D, we
performed a phenome–interactome network analysis (17) on
a published T1D GWLS that revealed 11 genomic regions with
linkage to T1D (3). Brieﬂy, genes located within 10 Mb on each
side of the most linked markers (Table 1) in the 11 regions were
used as input for the in silico generation of protein–protein in-
teraction networks. After the generation of these networks, dis-
ease phenotype association for all proteins in all networks was
determined, allowing scoring and ranking of individual candidate
proteins. A total of 11 proteins were predicted as candidate
proteins (Table 1), and their protein complexes are shown in Fig.
S1. Notably, insulin (INS), which is an established T1D candi-
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date gene (18, 19), was the highest-scoring candidate protein
predicted, thus providing proof of principle for the sensitivity of
the method and underlining the feasibility of this approach.
Another top-scoring candidate protein predicted by the method
was HIP14. The network for HIP14 contained 12 protein in-
teraction partners and is considered highly likely to be involved
in T1D, because it interacts physically with the huntingtin (HTT)
protein and glutamate decarboxylase 65 (GAD65), two proteins
that phenotypically are associated with diabetes (Fig. 1).
HIP14 was ﬁrst identiﬁed in 2002 and is widely expressed but
with highest expression in brain, where it colocalizes to Golgi and
cytoplasmic vesicle membranes (20). HIP14 possesses palmitoyl
transferase activity through a conserved cystein-rich domain
(DHHC motif) (21, 22). In neurons, HIP14 has high substrate
speciﬁcity for several vesicle-associated proteins, including syn-
aptosomal-associated protein 25 (SNAP)-25, GAD65, postsyn-
aptic density protein 95, synaptotagmin 1, and HTT (21, 23). On
the basis of these ﬁndings, we decided to examine the potential
functional role of HIP14 in the target tissue of T1D (i.e., the
β-cells in the islets of Langerhans).
HIP14 Is Predominantly Expressed in β-Cells. We ﬁrst wished to
demonstrate the presence of HIP14 in islets and β-cells. Western
blotting of HIP14 on lysates from insulin-producing rat INS-1
cells and isolated islets from rat, mouse, and human demon-
strated immunoreactive bands corresponding to HIP14, in-
dicating that HIP14 is expressed in islets and β-cells (Fig. 2A).
We then performed immunohistochemical analyses of mouse
pancreatic sections, which conﬁrmed staining of HIP14 in islets
(Fig. 2B). Interestingly, HIP14 staining appeared to be mainly
restricted to insulin-positive cells. Consistent with this notion,
comparison of HIP14 protein levels in an insulin-secreting β-cell
Table 1. T1D candidate proteins predicted by in silico phenome–interactome network analysis
Candidate protein Chromosome Nearest marker Score
INS, insulin 11p15 D11S922 0.9989
GLS, glutaminase C 2q-31-q33 D2S2167 0.9969
HIP14, huntingtin-interacting protein 14 12q14-q12 D12S375 0.9635
ASS1, arginino succinate synthetase 1 9q33-q34 D9S260 0.6472
HLA-DRA 6q21 TNFA 2 0.6405
SNTB2, syntrophin β-2 16q22-q24 D16S504 0.6036
HLA-DRB1 6q21 TNFA 1 0.3304
PKCD, protein kinase C-δ 3p13-p14 D3S1261 0.3237
JNK1, c-jun N-terminal kinase 1 10p14-q11 D10S1426 0.1900
AKD1, adenylate kinase domain containing 1 6q21 D6S283 0.1577
STX4, syntaxin 4 16p12-q11.1 D16S3131 0.1482
A total of 11 candidate proteins with scores above 0.1 were predicted. Brieﬂy, all proteins encoded by genes in
linkage intervals were identiﬁed and used for in silico construction of protein networks according to protein–
protein interaction information from several databases. Each protein in each network was then subjected to
text-mining for association to diabetes or similar phenotype. Each network was then scored and ranked by
a Bayesian predictor. Candidate proteins are listed according to their score.
IQGAP3
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LCK
PSD95
SNAP25
RRAS2 ARFGAP1
GNB4
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Fig. 1. Protein network for HIP14. The network consists of 12 interaction
partners, of which 2 (GAD65 and HTT) are phenotypically associated with
diabetes.
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Fig. 2. Expression of HIP14 in pancreatic islets. (A) Expression of HIP14 in rat
brain (positive control), INS-1 cells, and pancreatic islets from mouse, rat, and
human. Whole-cell lysates were subjected to immunoblotting using an anti-
HIP14 antibody. (B) Immunohistochemical stainings of mouse pancreatic
sections using antibodies against HIP14, insulin, and glucagon. Nuclei
staining was done using DAPI (gray). (C) Immunoblotting of HIP14 in
a mouse β-cell line (βTC3) and a mouse α-cell line (αTC1). (D) Quantiﬁcation
of HIP14 protein normalized to β-actin (n = 2–3).
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line (βTC3) vs. a glucagon-secreting α-cell line (αTC1) suggested
that β-cells express more HIP14 than α cells (Fig. 2 C and D).
Collectively, these results demonstrate that HIP14 protein is
expressed in pancreatic β-cells and provide the basis for inves-
tigations of the functional role of HIP14 in β-cells.
HIP14 Is Required for β-Cell Survival. The hallmark of T1D is the
induction of β-cell apoptosis by inﬂammatory mediators. We
therefore sought to investigate whether HIP14 may play a func-
tional role in the regulation of β-cell apoptosis. To examine this,
we applied RNAi to knockdown the expression of HIP14. We
used FACS-puriﬁed primary rat β-cells transfected with either
negative control siRNA (si-Neg) or siRNA against HIP14 (si-
HIP14). These experiments revealed that knockdown of HIP14
(≈70% knockdown efﬁciency; Fig. 3A) caused an increase in
the apoptotic cell death rate by 83% (Fig. 3B). To substantiate
this ﬁnding, we transfected INS-1 cells with expression vectors
encoding four different shRNA molecules, which are processed
intracellularly to active siRNAs targeting HIP14 mRNA. Trans-
fection with a vector encoding GFP revealed a transfection efﬁ-
ciency of ≈50% (Fig. 3C). The experiments showed that each
vector increased the basal apoptosis rate by ≈30% (Fig. 3D). In
line with these observations, we found that INS-1 cells transfected
with siRNA against HIP14 had a signiﬁcantly slower growth rate
than cells transfected with control siRNA (Fig. 3 E and F). These
ﬁndings suggest that HIP14 possesses antiapoptotic properties and
is required for survival of β-cells in vitro.
HIP14 Is Required for Glucose-Stimulated Insulin Secretion. HIP14
plays an important role in the regulation of vesicle exocytosis in
neurons (24). We therefore examined whether HIP14 is involved
in the exocytosis of insulin granules in β-cells. We ﬁrst measured
accumulated insulin release to the culture medium in cells after
HIP14 knockdown. INS-1 cells transfected with shRNAs against
HIP14 secreted ≈35% less insulin to the medium compared with
cells transfected with negative control shRNA (Fig. 4A). With
a transfection rate of ≈50%, these results indicate that insulin
release in sh-HIP14–transfected cells is reduced by ≈70%. To get
further insight into the mechanisms underlying HIP14-dependent
β-cell insulin release, we next transfected INS-1 cells with a mu-
tant form of HIP14 (ΔHIP14), which lacks the DHHC domain
necessary for the palmitoyl transferase activity. Similar to
knockdown of HIP14, introduction of ΔHIP14 into INS-1 cells
caused a reduction (≈25%) in chronic insulin secretion compared
with mock-transfected cells (Fig. S2). Transfection of cells with
a vector encoding full-length HIP14 caused a minor but signiﬁ-
cant decrease in insulin secretion (Fig. S2), reﬂecting that a too-
high cellular level of HIP14 also causes some degree of impair-
ment in the secretory activity.
We next performed glucose-stimulated insulin secretion (GSIS)
experiments to validate the involvement of HIP14 in stimulated
insulin release. For these experiments we used INS-1E cells,
which are more glucose sensitive than parental INS-1 cells (25).
These studies demonstrated that knockdown of HIP14 by siRNA
decreased GSIS by ≈40% (Fig. 4B). We further evaluated the
requirement of HIP14 for GSIS in RNAi experiments in which
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Fig. 3. HIP14 is required for β-cell survival. (A) Efﬁciency of siRNA-mediated
knockdown of HIP14 expression in FACS-puriﬁed primary β-cells was evalu-
ated by real-time PCR. Data are means ± SEM of n = 5. (B) Primary FACS-
puriﬁed rat β-cells were left untransfected (control) or transfected with
negative control siRNA (si-Neg) or siRNA against HIP14 (si-HIP14). Apoptosis
was evaluated using Hoechst/PI staining. Data are means ± SEM of n = 5. (C)
INS-1 cells were transfected with pGFP. A transfection efﬁciency of approx-
imately 50% was obtained. (D) INS-1 cells were transfected with negative
control shRNA (sh-Neg) or four different shRNAs directed against HIP14 (sh-
HIP14 1–4). Apoptosis was determined by Cell Death Detection ELISA mea-
suring the presence of cytosolic histone–DNA complexes (nucleosomes). Data
are means ± SEM of n = 4. *P < 0.05 vs. si-Neg. (E) INS-1 cell growth was
measured in real time as described inMaterials and Methods. Representative
growth curves from cells transfected with si-Neg or si-HIP14 are shown. Each
experiment was performed in triplicate. (F) Slopes of growth curves. Data
are means ± SEM of n = 3. *P = 0.012.
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Fig. 4. HIP14 is required for insulin release. (A) INS-1 cells were transfected
with negative control shRNA (sh-Neg) or four different shRNAs directed
against HIP14 (sh-HIP14 1–4). Accumulated insulin during 24 h was measured
in the culture medium. Data are means ± SEM of n = 5. *P < 0.05. (B) INS-1E
cells were transfected with either si-Neg or si-HIP14. Two days after trans-
fection, glucose-stimulated insulin secretion was determined by incubating
the cells in either 1.7 mM or 17 mM glucose in Krebs-Ringer buffer or RPMI
1640 for 30 min. Results are expressed as percentage of GSIS in si-Neg. Data
are means ± SEM of n = 4. P < 0.05.
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we used shRNAs against HIP14, which conﬁrmed involvement of
HIP14 in GSIS (Fig. S2). Glucose-induced release of human
growth hormone (hGH) has previously been described as a
measurement of exocytotic activity (26, 27). We therefore co-
transfected INS-1E cells with a vector encoding hGH and with
negative control siRNA or siRNA against HIP14 and measured
the ability of glucose to stimulate release of hGH. These ex-
periments further revealed that HIP14 is required for glucose-
induced secretory activity (Fig. S2). Together, these results
demonstrate that HIP14 is involved in the regulation of
insulin secretion.
Cytokines Suppress the Expression of HIP14. Proinﬂammatory
cytokines, in particular IL-1β, contribute to β-cell dysfunction
and apoptosis in T1D (28). We therefore next asked whether
cytokines regulate the expression of HIP14 in β-cells. Compared
with untreated control cells, exposure of INS-1 cells to IL-1β
alone or IL-1β plus IFN-γ for 24 h caused a reduction in the
cellular content of HIP14 (Fig. 5 A and B). In particular, the
combination of IL-1β and IFN-γ resulted in marked suppression
of HIP14 protein expression. Similar ﬁndings were obtained
using isolated intact rat islets (Fig. 5C). We also examined HIP14
expression in human islets and found that cytokines decreased
HIP14 expression in six of eight human islet donor preparations
(Fig. 5D). Collectively these results indicate that the expression
of HIP14 in β-cells is suppressed by proinﬂammatory cytokines.
To address the underlying mechanism of cytokine-mediated
down-regulation of HIP14 in β-cells, we examined whether
microRNAs are involved in repressing HIP14 expression after
cytokine treatment. Using two different microRNA target pre-
dictors publicly available (TargetScan 5.1 and Pictar), we
searched for microRNAs targeting HIP14 mRNA. MicroRNA
146a (miR146a) was predicted by both predictors to have HIP14
as target. Notably, previous ﬁndings demonstrated that cyto-
kines induce miR146a expression in clonal β-cells and isolated
islets (29). In line with the prediction that HIP14 is a target of
miR146a, transient transfection of INS-1 cells with miR146a
resulted in a markedly reduced HIP14 content (Fig. S2), in-
dicating that HIP14 indeed is targeted by miR146a in insulin-
secreting cells. These data suggest that miR146a may contribute
to cytokine-induced suppression of HIP14 expression in β-cells.
HIP14 Decreases IL-1β–Induced NF-κB Activation and Apoptosis. Be-
cause HIP14 is required for β-cell survival and because cytokines
down-regulate the expression of HIP14, we wanted to investigate
whether overexpression of HIP14 could protect against cytokine-
induced apoptosis. INS-1 cells were transfected with an empty
vector or plasmids encoding either HIP14 or ΔHIP14. After
exposure to IL-1β alone or IL-1β plus IFN-γ, apoptotic cell death
was measured. Compared with empty vector-transfected control
cells, cells transfected with HIP14 or ΔHIP14 were less sensitive
to IL-1β–induced apoptosis (Fig. 6A). However, apoptosis in-
duced by IL-1β plus IFN-γ was not modulated by overexpression
of HIP14 or ΔHIP14. This probably reﬂects that the apoptosis
rate caused by a mixture of cytokines is too high to be prevented
by HIP14, whereas the more moderate apoptosis level induced
by IL-1β alone can be suppressed. We also examined the effect
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Fig. 5. Cytokines suppress the expression of HIP14. (A) INS-1 cells were left
untreated or exposed to IL-1β (150 pg/mL) alone or IL-1β (150 pg/mL) plus
IFN-γ (5 ng/mL) for 24 h. Whole-cell lysates were subjected to immunoblot-
ting using anti-HIP14 and anti–β-actin antibodies. Representative blots of
four individual experiments are shown. (B) HIP14 protein in INS-1 cells was
quantiﬁed and normalized to β-actin. Data are means ± SEM of n = 4. (C)
Isolated rat islets were left untreated or exposed to IL-1β (150 pg/mL) plus
IFN-γ (5 ng/mL) for 24 h. Islet lysates were subjected to immunoblotting
using an anti-HIP14 antibody. HIP14 protein was quantiﬁed and data are
means ± SEM of n = 3. (D) Expression of HIP14 by real-time PCR in human
islet preparations from eight donors left untreated or exposed to cytokines
(75 U/mL IL-1β plus 750 U/mL IFN-γ plus 5,000 U/mL TNF-α) for 48 h. HIP14
transcripts were quantiﬁed and normalized to a geometric average of three
housekeeping genes (GAPDH, 18S-RNA, and PPIA). Data are expressed as
fold change after exposure to cytokines.
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Fig. 6. HIP14 decreases IL-1β–induced apoptosis. (A) INS-1 cells were trans-
fected with either an empty control vector (pcDNA) or vectors encoding
HIP14 or ΔHIP14. Two days after transfection, cells were left untreated or
exposed to IL-1β (150 pg/mL) or IL-1β (150 pg/mL) plus IFN-γ (5 ng/mL) for
24 h. Apoptosis was determined by Cell Death Detection ELISA measuring
the presence of cytosolic histone–DNA complexes (nucleosomes). Data are
means ± SEM of n = 2–4. *P < 0.01 vs. pcDNA plus IL-1β. (B) INS-1 cells were
transfected with an NF-κB–driven Luciferase Fireﬂy reporter gene construct
and with pcDNA, HIP14, ΔHIP14, or shRNAs targeting HIP14 (sh-HIP14). Cells
were then left untreated or exposed to IL-1β (150 pg/mL) for 4 h. Luciferase
activity was measured and results shown are means ± SEM of n = 3.
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of RNAi-mediated HIP14 knockdown on cytokine-induced
apoptosis and found that knockdown of HIP14 did not further
modulate cytokine-induced apoptosis (3.19 ± 0.40-fold vs. 3.45 ±
0.17-fold, P = 0.54, n = 3–4).
To gain insight into the putative mechanisms underlying the
protective effect of HIP14 against IL-1β–induced apoptosis, we
next investigated whether HIP14 affects IL-1β–induced activa-
tion of the transcription factor NF-κB, which is well known to
contribute to cytokine-induced apoptosis in β-cells (30, 31). Us-
ing an NF-κB–driven luciferase reporter gene construct, we
found that both HIP14 and ΔHIP14 reduced IL-1β–induced NF-
κB activity in INS-1 cells (Fig. 6B), suggesting that a possible
mechanism by which HIP14 decreases IL-1β–induced apoptosis
is via suppression of NF-κB transactivation.
Association Between SNPs and T1D and Transcription Factor Binding
Sites Upstream of HIP14. Finally, we looked for direct genetic as-
sociation of HIP14 with T1D. Genetic analyses were performed
in a T1D family material comprising DNA from 1,928 Danish
T1D families (6,853 individuals). According to information from
HapMap (www.hapmap.org), two linkage disequilibrium (LD)
blocks were found to cover the HIP14 gene on chromosome 12.
We selected one tagSNP in each of these blocks (rs4761444 in
intron 1 and rs17813975 in exon 8), as well as one SNP in the
promoter region (rs7956544 located 17 kb upstream of theHIP14
start site) to capture variation in the gene. However, we could not
demonstrate association to T1D of any of the SNPs analyzed
[P (transmission disequilibrium test) = 0.78, 0.42, and 0.49, re-
spectively]. This ﬁnding suggests that genetic variation in the
HIP14 gene and promoter per se is not associated with T1D. It
does not rule out the possibility, however, that there are rare
variants or genetic variation in the same chromosomal region but
outside the HIP14 gene and promoter that affect HIP14. To test
this hypothesis, we looked for genetic association using the full
genetic dataset from the recent GWAS and metaanalysis pub-
lished by the Type 1 Diabetes Genetics Consortium (4). We
identiﬁed SNPs that were nominally associated (P < 0.01) with
T1D in a region located >100 kb upstream of the HIP14/
ZDHHC17 locus. Because of a recombination hotspot that sep-
arated the associated SNPs from the HIP14 gene, there was no
LD between the associated SNPs and SNPs within HIP14 and
hence no direct association, supporting the observation made in
our genetic analysis of the T1D family material. The most sig-
niﬁcantly associated SNP (rs2632214, P = 0.0055), however, was
located 125 kb upstream of the transcriptional start site of HIP14
and could potentially affect a transcription factor binding site that
regulates the expression of HIP14 (Fig. S3). Using ENCODE
ChIP-seq data available at the University of California, Santa
Cruz genome browser (http://genome.ucsc.edu/), we identiﬁed
two regions of high-scoring transcription factor binding sites
surrounding rs2632214. The ﬁrst was located 3 kb downstream of
rs2632214 and contained an overlapping binding site for c-jun and
STAT1. The second one was located 2 kb upstream of rs2632214
and contained an overlapping binding site for multiple tran-
scription factors, of which BRG1 had the highest score. We ex-
amined the LD between rs2632214 and SNPs located within these
two transcription factor binding sites and found that rs2632214
was highly correlated with rs11114818 (r2> 0.9) within the binding
site for c-jun and STAT1, as well as with rs2632217 (r2 = 1.0) in
the binding site for BRG1 (Fig. S3). These ﬁndings suggest that
SNPs located in the nominally associated T1D region could affect
the expression of HIP14 by interrupting with one or more tran-
scription factor binding sequences.
Discussion
The genetic susceptibility to T1D involves a small number of
genes with large effects sizes and a large number of genes with
smaller contributions. Although GWAS studies have emerged
during the last years and enabled identiﬁcation of a large number
of chromosomal risk regions with small odd ratios, linkage
studies with the power of detecting larger risk loci still provide
valuable information and merit follow-up (32). The 11 candidate
genes/proteins identiﬁed by our current bioinformatics approach
originated from linkage regions for T1D (3). The use of protein
interaction information to pinpoint and prioritize positional
candidate genes in the linkage loci of T1D has been demon-
strated previously by Gao and Wang (16). However, this previous
study decreased the number of potential candidate genes without
any further functional prioritization or biological evaluation, as
presently done.
The top three ranked proteins (ranking score above 0.9) in our
study were INS, glutaminase C (GLS), and HIP14. Although INS
is already an established candidate gene (19), both HIP14 and
GLS are unknown in the context of diabetes. Glutamate, which is
produced by GLS, is mainly described as an extracellular mes-
senger in the brain (33). However, evidence that glutamate is
also is an intracellular messenger in β-cells regulating glucose-
induced insulin secretion has been provided (34). Interestingly,
we found GLS to be signiﬁcantly down-regulated to 79% ± 22%
(P = 0.02, n = 8) at the mRNA level by cytokines in human
islets. Future studies will be needed to clarify the role of GLS in
pancreatic β-cells. Some of the other predicted proteins included
c-jun N-terminal kinase 1 (JNK1), protein kinase C-δ (PKCD),
syntaxin 4 (STX4), and arginino succinate synthetase (ASS)
(Table 1). JNK1 plays a signiﬁcant role in mediating cytokine-
induced β-cell apoptosis (35, 36). Likewise, recent evidence from
transgenic mice with β-cell-speciﬁc overexpression of a dominant-
negative form of PKCD pointed toward that PKCD as an im-
portant regulator of β-cell apoptosis (37). Studies from STX4
heterozygous knockout mice and MIN6 β-cells implicated that
STX4 is required for glucose-stimulated ﬁrst-phase insulin se-
cretion (38). ASS regenerates arginine from citrulline, contrib-
uting to nitric oxide production and apoptosis in cytokine-treated
pancreatic β-cells (39, 40). Thus, several of the predicted T1D
candidate proteins in the present study have previously been
connected to the regulation of essential β-cell functions.
On the basis of our prediction of HIP14 as a candidate protein
in T1D, and because there were no previous studies directly
describing a role for HIP14 in relation to diabetes, we inves-
tigated the functional role of HIP14 in β-cells. In T1D, the β-cells
are speciﬁcally destroyed by an autoimmune attack involving
proinﬂammatory cytokines, and β-cells have been shown to be
particularly prone to apoptosis compared with other cells types
in pancreatic islets (28). We therefore investigated whether
HIP14 could be involved in the regulation of apoptotis in β-cells.
Transient knockdown of HIP14 expression in FACS-puriﬁed
primary rat β-cells revealed a signiﬁcant increase in apoptosis,
indicating that decreased HIP14 levels in β-cells lead to in-
creased apoptosis. In agreement with these ﬁndings in primary
rat β-cells, we found that inhibition of HIP14 expression by
transient knockdown in INS-1 cells inhibited cell growth and
induced apoptosis. Although the level of apoptosis induced by
knockdown of HIP14 in both primary and clonal β-cells was
modest (≈30–80% increase), it is important to keep in mind that
β-cell demise in T1D in man is a slowly progressing process
stretching over several years. Thus, even minor increases in β-cell
apoptotic cell death rates may be of high importance seen from
a pathogenic point of view. Transfection of INS-1 cells with
HIP14 or ΔHIP14 decreased IL-1β–induced apoptosis, suggest-
ing that HIP14 irrespective of its palmitoyl transferase activity
possesses antiapoptotic properties. Given that cytokines reduced
the expression of endogenous HIP14, it also suggests that cyto-
kines cause apoptosis via down-regulation of HIP14 in β-cells.
The protective effect of HIP14/ΔHIP14 on IL-1β–induced apop-
totic cell death was associated with a decrease in IL-1β–induced
NF-κB transactivation, as observed in reporter gene experiments.
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This ﬁnding is in line with previous reports showing that block-
ade of the NF-κB pathway protects against cytokine-mediated
β-cell death in vitro (30, 31).
HIP14 is important for intracellular trafﬁcking and exocytosis
in neurons (20, 21, 24, 41). Neurons and pancreatic β-cells have
highly overlapping phenotypes and share a similar exocytotic
machinery (42). We observed that knockdown of HIP14 ex-
pression resulted in a decrease in insulin release, both when
measuring long-term accumulated insulin in the culture medium
from INS-1 cells and when measuring short-term GSIS in INS-
1E cells. Several proteins involved in exocytosis, such as SNAP25
and CSP, are palmitoylated by HIP14 (21). Overexpression of
a mutant ΔHIP14 that lacks the palmitoyl transferase domain
also decreased accumulated insulin release, albeit this decrease
was less prominent than that caused by HIP14 knockdown. This
indicates that the palmitoyl transferase activity of HIP14 is im-
portant for β-cell insulin release, probably by palmitoylation of
proteins involved in the exocytotic machinery. This assumption is
in line with results from neurons whereby mutant HIP14 caused
decreased exocytotic activity that correlated with severe synaptic
mislocation of SNAP25 and CSP in Drosophila melanogaster (24,
41). Of note, SNAP25 is also expressed in pancreatic β-cells, and
its inhibition by IL-1β contributes to the loss of ﬁrst-phase insulin
release in response to glucose (43).
HTT, the causative protein for Huntingtons’s disease (HD), is
palmitoylated by HIP14 (20, 23), and a transgenic mouse model
of HD expressing mutant HTT (140 polyglutamine repeats in the
HTT gene) develops diabetes due to β-cell dysfunction (44, 45).
Patients with HD have lower acute-phase insulin response after
an oral glucose tolerance test and higher prevalence of diabetes
(46, 47). The biological function of HTT is not fully established,
but several studies indicated its involvement in the intracellular
transport of vesicles (48). Thus, a mutant HTT in β-cells de-
creases both efﬁciency of intracellular transport and stimulated
insulin secretion (49). This may be explained by an increased
interaction between mutant HTT and β-tubulin, leading to de-
creased intracellular transport and consequently decreased in-
sulin release (49). Moreover, palmitoylation of HTT by HIP14 is
important for the subcellular localization and prevention of in-
tracellular inclusion of HTT (23). Taking these observations and
the present results into consideration, we suggest that HIP14 and
HTT are both important for β-cell insulin secretory capacity.
Proinﬂammatory cytokines such as IL-1β and IFN-γ play an
important role in the destruction of β-cells in T1D (28, 50). The
intracellular pathways leading to apoptosis are not completely
understood, although it is known that pathways such as MAPK,
NF-κB, and STAT1 signaling and endoplasmatic reticulum stress
play important roles (50, 51). However, the exact genes and
proteins that are targeted by cytokine signaling and responsible
for promoting β-cell destruction are unclear. Interestingly, HIP14
was down-regulated at the protein level after cytokine treatment
in both INS-1 cells and primary rat islets. Furthermore, we found
that cytokines suppressed HIP14 mRNA expression in six of eight
human islet donor preparations. Collectively, these data indicate
that expression of HIP14 is decreased in the β-cells by a T1D-
relevant inﬂammatory stimulus. As a regulatory mechanism of
HIP14 gene suppression after cytokine exposure, we suggest that
miR146a could be essential. miR146 is induced by cytokines (29,
52) and was predicted to bind to the 3′ UTR of HIP14 mRNA. In
transfection experiments, we showed that expression of HIP14 is
signiﬁcantly reduced by miR146a. However, additional experi-
ments are needed to fully establish a potential role of miR146a in
the regulation of HIP14 expression in β-cells.
Although we identiﬁed HIP14 as a candidate gene in the
phenome–interactome analysis, we could not demonstrate T1D
association for any of the chosen tagSNPs covering the HIP14
gene and promoter in a large Danish T1D family material. We
cannot rule out, however, that there are rare variants and/or
other genetic variation in HIP14 that could be associated with
T1D. Likewise, the genetic variation could lie outside the HIP14
gene and was therefore not detected in the present study. In line
with this, we identiﬁed a SNP (rs2632214) 125 kb upstream
HIP14 that is nominally associated with T1D when using the
detailed information from a recently published GWAS dataset
(4). Further analysis revealed that this SNP was in LD (r2 > 0.9)
with SNPs located in predicted transcription factor binding sites
for c-jun/STAT1 and BRG1. We speculate that these SNPs may
have an impact on the transcriptional regulation of HIP14, which
would inﬂuence β-cell insulin secretion and turnover.
Concluding Remarks. In the present study, we have used an in-
tegrative bioinformatics approach and identiﬁed 11 T1D candi-
date proteins. A top-scoring candidate protein was HIP14, which
we selected for functional studies, and we provide evidence that
HIP14 regulates apoptosis and insulin secretion in pancreatic
β-cells. Thus, our study demonstrates the feasibility and high
impact of integrating genetic information and protein–protein
interaction data to predict valid candidate proteins that may lead
to novel treatment strategies for T1D.
Materials and Methods
Immunohistochemistry. Pancreata obtained from adult NMRI mice were ﬁxed
in 4% paraformaldehyde overnight and transferred to 70% EtOH until par-
afﬁn embedding. Four-micrometer-thick sections were cut on a microtome.
Subsequently parafﬁn sections were deparafﬁnized with 3× Xylene, 3× 99%
alcohol, 3× 96% EtOH, 1× 70% EtOH, and ﬁnally rinsed in tap water, 5 min
each step. Sections were then microwaved in TEG buffer (10 mM Tris, 0.5 mM
EGTA) for 4 min at 600 W in 200 mL buffer followed by 15 min at 250 W and
ﬁnally left to cool for 20 min and incubated with 1% H2O2 in PBS for 30 min
and subsequently blocked with 0.5% tris-NaCl blocking reagent (Perkin-
Elmer). Sections were incubated with rabbit anti-HIP14 antibody (1:1,000;
Sigma H7414) overnight at room temperature. The following day sections
were rinsed in PBS, and biotinylated donkey anti-rabbit antibody (1:300;
Jackson ImmunoResearch) was added and incubated for 45 min. Sections
were then incubated with streptavidin-HRP, washed in PBS, and TSA-cy3
(tyramide signal ampliﬁcation; Perkin-Elmer) was added, and sections were
washed with PBS. On top of this new primary antibodies were added: guinea
pig anti-insulin (1:150; Abcam ab7842) andmouse anti-glucagon (1:100; Novo
Biolabs Glu001). Guinea pig antibody was visualized with donkey anti-guinea
pig-cy5 and mouse antibody with donkey anti-mouse-cy2 (1:300; Jackson
ImmunoResearch). DAPI (0.2 μg/mL) was used to stain nuclei. Images were
taken on an LSM510 LASER SCANNING confocal microscope (Zeiss). False color
images were generated with the LSM software. Final brightness/contrast
picture adjustment and layout of the ﬁgures were done using Canvas soft-
ware. Control experiments verifying the speciﬁcity of the anti-HIP14 antibody
(Sigma H7414) used for staining are shown in Fig. S4.
Cell Culture. Primary neonatal rat islets were isolated from 3- to 6-d-oldWistar
rats (Taconic) and precultured for ≈7 d in RPMI1640 containing 10% new-
born calf serum and 100 U/mL penicillin and 100 μg/mL streptomycin (all
from Invitrogen). Randomly picked islets were placed in 12-well dishes
(Nunc) and left untreated or stimulated with cytokines for 24 h in RPMI 1640
supplemented with 10% FBS and penicillin/streptomycin. Recombinant
mouse IL-1β was from BD Pharmingen, and recombinant rat IFN-γ was
obtained from R&D Systems. Isolation and culture of primary FACS-sorted rat
β-cells (>90% purity) was performed as previously described (53, 54). INS-1
cells were maintained in RPMI 1640 medium (11 mM glucose) supplemented
with 10% FBS, 100 U/mL penicillin, and 100 μg/mL streptomycin (all from
Invitrogen). In addition, the media contained 50 μM β-mercaptoethanol.
Cells were trypsinized and passaged weekly. Human pancreatic islets were
obtained from a multicenter European Union-supported program on β-cell
transplantation in diabetes directed by Prof. D. Pipeleers. The program has
been approved by central and local ethics committees. Human islet prepa-
rations were obtained from eight donors (aged 8–57 y); six were male
donors, and two were female. Each preparation was stimulated with a mix-
ture of cytokines [TNF-α (5,000 U/mL), IFN-γ (750 U/mL), and IL-1β (75 U/mL)]
for 48 h.
Immunoblotting. For preparation of whole-cell extracts, cells or islets were
lysed for 30 min on ice in lysis buffer containing 20 mM Tris-acetate (pH 7.0),
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0.27M sucrose, 1mMEDTA, 1mMEGTA, 50mMNaF, 1% vol/vol Triton X-100,
5 mM sodium pyrophosphate, 10 mM sodium glycerophosphate, 1 mM
benzamidine, 1 mM DTT, 1 mM Na3VO4, and 4 μg/mL leupeptin. Detergent-
insoluble material was pelleted by centrifugation at 15,000 × g for 5 min at
4 °C. The supernatants (whole-cell extracts) were stored at −80 °C until fur-
ther use. Protein concentrations in lysates were determined by the Bradford
method using the dye reagent concentrate (Bio-Rad). Cell lysates were
denatured by addition of 4× lithium dodecyl sulphate sample buffer (Invi-
trogen) and heating for 5 min at 70 °C. Samples were then subjected to 10%
SDS/PAGE followed by electro-transfer onto nitrocellulose membranes.
Membranes were blocked in 1× Tris-buffered saline (pH 7.6) containing 0.1%
Tween 20 (TBST) and 5% nonfat dry milk for 1 h before primary antibody
was added (anti-HIP14; Sigma H7414 diluted 1:250–500 in TBST with 5%
dry milk). Filter membranes were incubated with primary antibody at 4 °C for
1–2 d and then washed in TBST and incubated with secondary horseradish
peroxidase-conjugated antibodies for 1 h. Immune complexes were detected
by chemiluminescence using LumiGLO (Cell Signaling), and images were
digitally captured using a FUJI LAS3000. To verify the speciﬁcity of the anti-
HIP14 antibody (Sigma H7414), HEK293 cells were transfected using Lip-
ofectamine 2000 (Invitrogen) with an expression vector encoding HIP14. The
lysates were then examined by immunoblotting (Fig. S4).
Cell Growth. Cell growth was measured in real time using an xCELLigence
apparatus (Roche). INS-1 cells were seeded (3.0 × 104 cells/well) in standard
culture conditions in 96-well E-plates. Background impedance was de-
termined according to the manufacturer’s protocol. The plate was incubated
for 30 min at room temperature before installation into the Real-Time Cell
Analyzer station in a conventional cell incubator at 37 °C and 5% CO2. After
24 h the culture medium was changed to antibiotic-free medium and the
cells transfected. The transfection medium was changed to normal culture
medium after 24 h. The impedance was measured every 15 min and
expressed as cell index (CI), deﬁned as (Rn − Rb)/15, where Rn represents the
impedance at a given time point, and Rb is the background impedance. The
normalized CI was determined by the CI at a given time point divided with
the CI at the normalization time point. Slopes of growth curves were de-
termined between the time points “day 1” and “day 3” [i.e., from the time
point when the medium was changed (24 h after transfection) to the time
point when si-Neg-transfected cells reached conﬂuence (peak)].
Apoptosis Measurements. Apoptosis in primary FACS-sorted β-cells was de-
termined by propidium iodine (PI) and Hoechst staining as previously de-
scribed (54). Apoptotic cell death in INS-1 cells was determined by the
detection of DNA-histone complexes present in the cytoplasmic fraction of
cells using the Cell Death Detection ELISAPLUS assay (Roche) as described by
the manufacturer. Brieﬂy, after exposure of cells to the desired reagents, the
culture medium was removed and the cells lysed in 400 μL lysis buffer for 30
min at room temperature. Lysates were centrifuged for 10 min at 200 × g and
20 μL supernatant and 80 μL immunoreagent (anti-DNA-POD antibody and
anti-histone-biotin antibody) were added to streptavidin-coated microtiter
plates and incubated for 2 h under shaking conditions (300 rpm) at room
temperature. The solution was then removed and each well washed three
times with 250 μL incubation buffer, after which 100 μL ABTS (2,2-azino-bis-3-
ethylbenzthiazoline-6-sufonate) solution was added. Absorbance was mea-
sured at 405 nm and 490 nm.
RNAi and Transfection. Primary FACS-puriﬁed β-cells were transfected with
TARGETplus SMARTpool siRNA listed below, and transfection was performed
as in ref. 54. INS-1 cells were cultured in 24-well (0.2 × 106 cells/well) or 96-well
(3.0 × 104 cells/well) plates. Before transfection, the cells were cultured in
antibiotic-free medium for at least 4 h. The siRNAs (ON-TARGETplus
SMARTpool; Thermo Scientiﬁc) directed against rat HIP14 were used with
the target sequences: AGGUUAUGACGUACGGCAA, UAUGAACGCUGCCGA-
GAAU, GUACAUAGCACAUGCGAAU, and GGACAAAGAGAACGUUACA. For
the miR-146a transfection experiments we used miR-146a miRIDIAN mimic
(#C-300630-03), and as control we used miRIDIAN negative control (#CN-
001000-01) (Thermo Scientiﬁc). Expression plasmids encoding HIP14 and
ΔHIP14 (21) were kindly provided by Dr. Alaa El-Husseini (University of British
Columbia, Vancouver, BC, Canada). The vector encoding human growth
hormone (pXGH5) was kindly provided by Dr. Romano Regazzi (University of
Lausanne, Switzerland). Negative control siRNA (AllStars Negative Control
siRNA) was purchased from Qiagen. The shRNA vectors (SureSilencing, cata-
log no. KR54358N) targeting HIP14 and control vector were purchased from
SABiosciences. The siRNA or vectors and the DharmaFECT 1 solution (Thermo
Scientiﬁc) were diluted separately in OptiMEM and incubated for 5 min at
room temperature. Afterward, the two dilutions were mixed and incubated
for 20 min at room temperature to allow complex formation. This mixture
was subsequently diluted ﬁve times in antibiotic-free medium and added to
the cells at a ﬁnal concentration of 30 nmol/L siRNA or 2.5 μg/mL vectors and
1.5 μL/mL DharmaFECT. The cells were then incubated overnight. The next
day themediumwas changed to standard culturemedium, and the cells were
incubated for at least 24 h before analysis or further experimentation.
Accumulated Insulin and Glucose-Induced Insulin Secretion. Accumulated in-
sulin in culture medium or glucose-induced insulin release to Krebs Ringer
buffer were determined as previously described (55). For glucose-stimulated
insulin release, 0.12 × 106 INS-1E cells were seeded in 24-well dishes. Trans-
fection with siRNAs or vectors was conducted as described above. After a re-
covery period of 24 h, the cells were starved for 1 h in Krebs Ringer buffer
without glucose. Afterward the cells were exposed to Krebs Ringer buffer or
culture medium containing either 1.7 mM or 17 mM glucose for 30 min.
Gene Expression Analysis.mRNAwas extracted from human islet preparations
by TRIzol according to the manufacturer’s protocol (Invitrogen). cDNA was
prepared from total RNA by oligo-dT–primed reverse transcription, as de-
scribed by the manufacturer (TaqMan RT reagents; Applied Biosystems).
Relative expression levels of HIP14 (TaqMan primer Hs00392305_m1) and the
house-keeping genes (PPIA, GAPDH, and 18S) were evaluated by the use of
TaqMan assays. The Low Density Array system (Applied Biosystems) con-
taining assays for the individual genes as well as housekeeping genes was
used on TaqMan 7900HT (Applied Biosystems). For evaluation, expression
levels of genes were normalized against the geometric mean of three
housekeeping genes and evaluated using the ΔΔCT method (56). For pri-
mary FACS-sorted rat β-cells, RNA extraction, cDNA synthesis, and real-time
PCR were conducted as previously described (54).
Luciferase Reporter Gene Assay. INS-1 cells (0.15 × 106 cells) in duplicates were
transfected with an NF-κB–driven luciferase reporter construct containing
ﬁve repeats of NF-κB consensus binding sites (0.4 μg/well) (Stratagene) and
cotransfected with 0.5 μg/well of either empty vector (pcDNA) or vectors
encoding HIP14 or ΔHIP14 using the transfection reagent Superfect (Qia-
gen). Two days after transfection, cells were stimulated with IL-1β for 4 h.
Luciferase activity was measured by the dual luciferase reporter system
according to the speciﬁcations of the manufacturer (Promega).
Genetic Analyses. T1D families were ascertained through the Danish Society of
Childhood Diabetes, a population-based cohort, and were all of Danish Cau-
casoid origin. Probands in these families were diagnosed with T1D before 15 y
of age and had continued insulin treatment since diagnosis. For genotyping,
commercially available predesigned TaqMan SNP genotyping assays were used
(Applied Biosystems) with TaqMan 7900 HT equipment (Applied Biosystems).
SNPs genotyped were rs4761444, rs17813975, and rs7956544. All three SNPs
were previously evaluated in the HapMap project and were common in Cau-
casian populations (minor allele frequencies: 0.4, 0.19, and 0.45, respectively).
Association to T1D was evaluated by means of the transmission disequilibrium
test in PLINK (http://pngu.mgh.harvard.edu/~purcell/plink/summary.shtml).
The summary statistics were retrieved from the full GWAS and meta-
analysis dataset generated by the Type 1 Diabetes Genetics Consortium (4).
The genetic association P values across the HIP14/ZDHHC17 locus were vi-
sualized using the web-based software LocusZoom (57). The SNP rs2632214
had the lowest P value in a region located 125 kb upstream of HIP14. The
chromosomal region surrounding rs2632214 was examined for potential
transcription factor binding sites using the ENCODE ChIP-seq data available
at the University of California, Santa Cruz genome browser (http://genome.
ucsc.edu/). SNPs located within sequences occupied by transcription factors
were investigated for LD with rs2632214 using phase II genotypes for the
HapMap CEU samples (www.hapmap.org) in Haploview (58).
Statistical Analysis. In bar graphs, data are means ± SEM. Student’s paired t
test was used for statistical analysis. P < 0.05 was considered signiﬁcant.
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